Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat sarcoma viral oncogene (KRAS) mutation or to patients resistent to cetuximab and irinotecan therapy for metastatic colorectal cancer.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2109274 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA